Clinical trialNCT01136772CompletedPhase 4Interventional

A Comparison of Long-acting Injectable Medications for Schizophrenia

SponsorNew York State Psychiatric InstituteEnrollment311Schizoaffective DisorderSchizophrenia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Joseph P McEvoy, MD
Duke University
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Scott Stroup, MD, MPH
Columbia University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

22 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Va Palo Alto Heathcare Systems
Palo Alto, California, United States
Yale University/connecticut Mental Health Center
New Haven, Connecticut, United States
University of Miami School of Medicine
Miami, Florida, United States
Medical College of Georgia
Augusta, Georgia, United States
University of Iowa Hospital
Iowa City, Iowa, United States
Clinical Research Institute
Wichita, Kansas, United States
Clinical Insights, Inc.
Glen Burnie, Maryland, United States
John D. Dingell Va Medical Center
Detroit, Michigan, United States
Sparrow St. Lawrence Hospital, Michigan State University Psychiatry
Lansing, Michigan, United States
Kansas City Veterans Affairs Medical Center
Kansas City, Missouri, United States
Creighton University Dept. of Psychiatry
Omaha, Nebraska, United States
Research Foundation for Mental Hygiene
New York, New York, United States
University of Rochester
Rochester, New York, United States
John Umstead Hospital/duke University
Butner, North Carolina, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Carolina Behavioral Care
Durham, North Carolina, United States
Louis Stokes Cleveland Va Medical Center
Brecksville, Ohio, United States
Philadelphia Va Medical Center-116a
Philadelphia, Pennsylvania, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Central Texas Veterans Health Care System
Waco, Texas, United States
Frontier Institute
Spokane, Washington, United States
Va Puget Sound Health Care System
Tacoma, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Haloperidol →Paliperidone →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2011
Primary completion: 31 Jul 2013
Completion: 31 Jul 2016
Last update posted: 21 Oct 2016
Registered enrollment: 311
Registry id: NCT01136772

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.